Lizhu Group: It is expected that overseas formulation profits will more than double compared to last year.

The Lizhu Group stated in a conference call on April 24 that, from the perspective of profit and sales growth, the company's overseas formulation business will enter a clear and incremental cashing period, with the inflection point of compound growth rate starting this year. By 2026, IMP will be consolidated, with the current annual income scale of IMP being about 800 million RMB, achieving a compound annual growth rate of over 10% in the past 5 years. In addition to the impact of IMP consolidation, substantial overseas sales of formulations will also reach a turning point in the validation of commercial value. It is expected that overseas formulation profits will achieve about twice the year-on-year growth this year, mainly driven by cooperation authorization fees for key overseas varieties such as assisted reproduction and Cime.